文献速递前列腺癌

机器人辅助腹腔镜前列腺切除术后pT3b前列腺癌的当前管理

Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy.
PubMed 文献 · Eur Urol Oncol · 2018-05-27

基于比利时RALP前瞻性注册研究(2009年10月至2016年3月)的796例pT3b前列腺癌患者,评估机器人辅助根治性前列腺切除术后当前临床实践中的管理。85%临床高危局部进展患者接受盆腔淋巴结清扫,术后早期并发症8.5%;中位随访12个月时63%的pN1患者和56%的R+患者接受追加治疗,但15-21%患者未获得充分盆腔淋巴结分期,38%患者接受辅助治疗。

要点

  • pT3b前列腺癌RALP术后并发症可接受,早期并发症率8.5%。
  • 中位随访12个月,63%的pN1患者和56%的R+患者接受追加治疗。
  • 尽管有推荐,15-21%患者未获得充分盆腔淋巴结分期,38%接受辅助治疗。

核心结论

  • 当前实践中,RALP用于精囊侵犯前列腺癌的并发症可接受,术后追加治疗的使用受不同患者、肿瘤和手术变量影响。
  • 尽管有推荐,15-21%患者未获得充分盆腔淋巴结分期,38%患者接受辅助治疗。
  • 完整且正确地分期真实疾病范围在这些患者的管理中仍然重要。

研究设计与样本

  • 比利时RALP联盟前瞻性项目(2009年10月至2016年3月)的一部分,评估796例pT3b前列腺癌患者。
  • 干预为机器人辅助根治性前列腺切除术。
  • 采用多变量回归分析识别淋巴结侵犯(pN1)、手术切缘阳性(R+)、术后并发症和追加治疗的独立预测因素。

主要发现

  • 85%的临床高危局部进展前列腺癌患者接受盆腔淋巴结清扫。
  • 术后早期并发症(0-30天)见于68例患者(8.5%)。
  • 肿瘤学随访(中位12个月)期间,63%的pN1患者和56%的R+患者接受追加治疗。
  • 实施盆腔淋巴结清扫(评估pN1状态所必需)仅为雄激素剥夺治疗的特异性预测因素,而R+和较年轻年龄仅为放疗的独立预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性包括各医院间追加治疗策略非标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Robot-assisted radical prostatectomy (RALP) in high-risk and locally advanced prostate cancer (PCa) is gaining increasing traction. The optimal use of additional treatments for PCa with seminal vesicle invasion (pT3b) after RALP remains ill explored. OBJECTIVE: To evaluate the management of pT3b PCa after RALP in current clinical practice. DESIGN, SETTING, AND PARTICIPANTS: As part of the prospective Belgian RALP Consortium project (October 2009-March 2016), 796 patients with pT3b disease were evaluated. INTERVENTION: Robot-assisted radical prostatectomy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Population and perioperative characteristics were described to assess surgical outcome. Multivariable regression analyses were used to identify independent predictors of lymph node invasion (pN1), positive surgical margins (R+), postoperative morbidity, and additional treatments. RESULTS AND LIMITATIONS: In this prospective population-based registry, 85% of patients with clinical high-risk locally advanced PCa received pelvic lymph node dissection (PLND). Early postoperative complications (0-30 d) were observed in 68 patients (8.5%). During oncologic follow-up (median 12 mo), 63% of pN1 patients and 56% of R+ patients received additional therapy. Performing PLND (necessary for assessing pN1 status) was a specific predictor for androgen deprivation therapy only, whereas R+ and younger age were independent predictors for radiotherapy only. Limitations include the nonstandardized policy on additional treatments among hospitals. CONCLUSIONS: In current practice, RALP is performed with acceptable morbidity for PCa with seminal vesicle invasion and the use of postoperative additional treatments is influenced by different patient, tumor, and surgical variables. Despite the recommendations, 15-21% of patients do not receive adequate pelvic lymph node staging and adjuvant therapy is given in 38% of patients. Full and correct staging of the real disease extent remains important in the management of these patients. PATIENT SUMMARY: This study on prostate cancer with seminal vesicle invasion after robot-assisted prostatectomy evaluates the use of additional treatments in current clinical practice. Additional treatments for advanced prostate cancer should be patient-adjusted according to the disease extent.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Poelaert F, Joniau S, Roumeguère T, et al. Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy. Eur Urol Oncol. 2018. PMID: 30929840. doi:10.1016/j.euo.2018.05.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。